1. Home
  2. ELOG vs KPRX Comparison

ELOG vs KPRX Comparison

Compare ELOG & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eastern International Ltd. Ordinary Shares

ELOG

Eastern International Ltd. Ordinary Shares

HOLD

Current Price

$0.81

Market Cap

10.5M

Sector

Industrials

ML Signal

HOLD

Logo Kiora Pharmaceuticals Inc.

KPRX

Kiora Pharmaceuticals Inc.

HOLD

Current Price

$2.64

Market Cap

11.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELOG
KPRX
Founded
2006
1998
Country
China
United States
Employees
N/A
13
Industry
Integrated Freight & Logistics
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.5M
11.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ELOG
KPRX
Price
$0.81
$2.64
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
5.5K
20.6K
Earning Date
07-17-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$6.84
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.73
$1.76
52 Week High
$3.07
$2.99

Technical Indicators

Market Signals
Indicator
ELOG
KPRX
Relative Strength Index (RSI) 37.40 50.91
Support Level N/A $2.44
Resistance Level $1.00 $2.61
Average True Range (ATR) 0.07 0.09
MACD -0.01 0.00
Stochastic Oscillator 0.00 82.35

Price Performance

Historical Comparison
ELOG
KPRX

About ELOG Eastern International Ltd. Ordinary Shares

Eastern International Ltd is a holding company. The company operates through its subsidiary engaged in domestic and cross-border professional logistic services including project logistics and general logistics for company clients. Its project logistic services include Construction project logistics and special cargo logistics for large or precision equipment and General logistic services refer to the transportation, warehousing, loading and unloading, and distribution of ordinary products.

About KPRX Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Share on Social Networks: